Tag Archives: U.S. Patent and Trademark Office

USPTO Blogpost Brings Mayo Down to Earth

Kappos-200

The United States Patent and Trademark Office Director David Kappos posted a blogpost called “Some Thoughts on Patentability” which discusses a recent Federal Circuit decision in CLS Bank International v. Alice Corporation and the lessons we should learn from the Federal Circuit.  “Based on my experience, I appreciate the wisdom of the court’s discussion relating to resolving disputed claims by focusing initially on patentability requirements of § 102, 103, and 112, rather than § 101. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Exclusive Licenses Do Not Discourage Follow On Research

medical_research_thumb

A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions.  First, does exclusive licensing affect licensee follow-on research?  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Critical Importance of International Patent Protection for Small Businesses

Stanley Erck

As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection.  Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Joins 261 Business, Research Institutions and Organizations to Urge Caution in Microsoft v. i4i Case*

*UPDATE – 90 more organizations have decided to add their names to the letter sent to the Department of Justice.  Please find the new letter. Please find attached an open letter to Attorney General Holder and Acting Solicitor General Katyal, signed by 171 businesses, research institutions and organizations of all sizes, representing U.S. innovation in all 50 states and the District of Columbia. The signatories include leading innovators in agriculture, biotechnology, consumer products, electrical, mechanical  and Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO’s Comments on proposed PTO Humanitarian Technologies and Licensing Through the Intellectual Property System

Here are the highlights from BIO’s recent submission on the proposed PTO “Request for Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System.”   Background: 1.  “BIO’s members also understand that problems with access to medicines and other biotechnology products in the developing world have very little to do with the patent system, and are generally caused by other factors outside the control of individual stakeholders, such as lack of adequate local manufacturing, Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,